Previous 10 | Next 10 |
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates - Company is advancing its integrin program and on schedule for initiating clinical studies in 2023 - Expanding immuno-oncology pipeline through strategic transac...
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems...
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer - Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Uni...
Last week was mixed for the penny stocks and higher-priced ones alike. While there were plenty of trends to follow, some continued gaining steam heading into the middle of November. Sure, you’ve got things like metaverse stocks, short squeeze penny stocks , and your typical low f...
Corbus Pharmaceuticals (NASDAQ:CRBP): Q3 GAAP EPS of -$0.02 beats by $0.10. Revenue of $0.1M (-91.9% Y/Y) misses by $0.43M. Press Release As of September 30, 2021, the company has $108M of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based ...
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates - Company continues to advance integrin program from preclinical development toward the clinic - Expanding pipeline through strategic transactions remains key priority - Ca...
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference - Fireside chat webcast will be available beginning on Thursday, November 18th at 8:00 AM GMT (3:00 AM ET) PR Newswire NORWOOD, Mass. , Nov. 11, 2021 /PRNewswire/ -- Corbus Pharma...
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jac...
Corbus Pharmaceuticals (NASDAQ:CRBP): Q2 GAAP EPS of -$0.15 misses by $0.03. Revenue of $0.14M (-53.3% Y/Y) misses by $0.57M. Shares -1.5% PM. Press Release Cash and investments on hand of $114M provides projected runway into first quarter of 2024 For further details see: Corbus Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
2024-03-28 01:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) traded at a new 52-week high today and are currently trading at $48.34. So far today, approximately 46,795 shares have been exchanged, as compared to an average 30-day volume of 332.46k shares. Corbus Pharmaceuticals Holdings, Inc...
Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study on track to commence in Summer of 2024 Pre-clinical data for CRB-913 presented ...